#TALK Research - December Newsletter
11/12/2025
As the end of the year approaches, it is encouraging to reflect on ACTT’s strong performance across a broad range of therapeutic areas. Our involvement in cutting-edge research, including modern CRISPR therapies for rare diseases and inherited cholesterol disorders, and next generation of triple agonists in the metabolic space – continues to put Aotearoa on the map.
Read more








